NidoVax is developing novel vaccines targeting COVID-19. We employ a cutting-edge vaccine technology called IMT504. IMT504 is combined with important parts of the virus, to rapidly confer robust, long-lasting protection. We have the ability to very rapidly generate and test multiple vaccines, which can be quickly advanced to human testing.

NidoVax's vaccine platform technology benefits from 8 years of development and $23 million in R&D funding